ArticleJournal of immunology (Baltimore, Md. : 1950)2014
CD19 and CD32b differentially regulate human B cell responsiveness.
Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 50 citations in OpenAlex.
- Impaired Antibody-Independent Immune Response of B Cells in Patients With Acute Dengue Infection.Frontiers in immunology · 2019Trial
- Trial
- Exploratory Immunohistochemical Profiling of FOXP3, PD-1 and CD32B in Resectable Lung Adenocarcinoma.Cancers · 2025Article
- Somatic Mutations in DNA Mismatch Repair Genes, Mutation Rate and Neoantigen Load in Acute Lymphoblastic Leukemia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Ramping up the Heat: Induction of Systemic and Pulmonary Immune Responses and Metabolic Adaptations in Mice.bioRxiv : the preprint server for biology · 2025Article
- Induced proximity at the cell surface.Nature biotechnology · 2025Review
- State-of the-art and future perspective in co-culture systems for tendon engineering.Biomaterials and biosystems · 2025Article
- Multimodal hierarchical classification of CITE-seq data delineates immune cell states across lineages and tissues.Cell reports methods · 2025Article
- Multimodal hierarchical classification of CITE-seq data delineates immune cell states across lineages and tissues.bioRxiv : the preprint server for biology · 2024Article
- Synergistic B and T lymphocyte interaction: prognostic implications in non-small cell lung cancer.American journal of cancer research · 2024Article
- Inherited CD19 Deficiency Does Not Impair Plasma Cell Formation or Response to CXCL12.Journal of clinical immunology · 2023Article
- A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases.JCI insight · 2023Article
- CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2023Article
- Disrupting N-Glycosylation Using Type I Mannosidase Inhibitors Alters B-Cell Receptor Signaling.ACS pharmacology & translational science · 2022Article
- Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage.Cancers · 2022Review
- Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2022Review
- Dihydroarteannuin Ameliorates Collagen-Induced ArthritisFrontiers in pharmacology · 2022Article
- FcγRIIB is a T cell checkpoint in antitumor immunity.JCI insight · 2021Article
- B Cells in Rheumatoid Arthritis：Pathogenic Mechanisms and Treatment Prospects.Frontiers in immunology · 2021Review
- Abundance and Expression of Shiga Toxin Genes inFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
B cell activation is regulated by a variety of signals. CD19 positively regulates B cell activation, augmenting signals delivered through the BCR complex. In contrast, CD32b contains an ITIM and negatively regulates BCR signaling. Importantly, there are drugs currently in clinical trials and preclinical development that cross-link CD32b to molecules within the BCR complex. We wanted to address how single engagement versus cotargeting these molecules affects human B cell function. When B cells from healthy individuals were activated by signals that mimic a T cell response (IL-21 costimulation), ligation of CD32b, but not CD19, inhibited B cell expansion and plasma cell (PC) differentiation. In contrast, when B cells were activated through TLR, anti-CD19, but not anti-CD32b, blunted the response. However, when both CD19 and CD32b were coengaged by a bispecific anti-CD19×CD32b Ab, both types of stimuli were potently inhibited. Cross-linking CD19 with CD32b also inhibited Ab-independent functions of B cells, such as HLA upregulation, cytokine production, and the ability of B cells to prime CD4(+) T cells. Finally, although cross-linking CD19 and CD32b inhibited PC differentiation of primary B cells, it did not alter Ig production from pre-established PCs. These data elucidate the mechanism by which a complex set of signals determines the fate of B cell responsiveness. Although signals through CD19 influence TLR-driven activation, CD32b impacts the magnitude of the response following IL-21 costimulation. Therefore, simultaneous targeting of multiple surface molecules may be a necessary approach to comprehensively modulate B cell activation in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.